Who We Are
Biologics by McKesson specialty pharmacy is a leader in creating truly exceptional patient experiences by simplifying connections for providers and delivering personalized care for every patient who we have the honor of serving.
We Focus on Our Patients
At Biologics, we focus on why we do what we do: our patients and the partners we work with. As an independent specialty pharmacy, we specialize in cancer and rare disease areas. Our goals are to simplify access to therapies and deliver personalized clinical care that helps patients understand how to take their medication, manage side effects and achieve the best-possible outcomes. We also provide benefits investigation, assist with prior authorizations and help patients find financial aid so they can afford their treatment.
Take a look at what our patients have to say about their experience with us.
Setting the Standard
With over 25 years’ experience caring for patients with cancer and other complex and rare diseases, Biologics has a strong foundation of clinical care with our multidisciplinary care team, and we’ve built on that approach by layering in partnerships, programs and technology that allow us to further elevate the way we care for our patients and the access we can provide them.
What can we help you with today?
Biologics by McKesson News
FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Aadi Bioscience as a specialty pharmacy...
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two...
KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two...